{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:14Z","timestamp":1791658094153,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","award":["101107022"],"award-info":[{"award-number":["101107022"]}],"id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["RADIOBIO 101042537"],"award-info":[{"award-number":["RADIOBIO 101042537"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008221","name":"Cure Starts Now Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijrobp.2025.06.3855","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:40:48Z","timestamp":1751424048000},"page":"177-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-2625","authenticated-orcid":false,"given":"Justine","family":"Perrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Overdevest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tamborino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-7522","authenticated-orcid":false,"given":"Julie","family":"Nonnekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148692","article-title":"The current understanding of the immune landscape relative to radiotherapy across tumor types","volume":"14","author":"Iliadi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2018.12.002","article-title":"Immune mechanisms mediating abscopal effects in radioimmunotherapy","volume":"196","author":"Rodriguez-Ruiz","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00262-016-1914-6","article-title":"Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment","volume":"66","author":"Ishihara","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7150\/thno.51215","article-title":"Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response","volume":"11","author":"Feijtel","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0005","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1358\/dot.2023.59.1.3476574","article-title":"Lutetium Lu 177 vipivotide tetraxetan for prostate cancer","volume":"59","author":"Liu","year":"2023","journal-title":"Drugs Today"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fmed.2015.00012","article-title":"Introduction to radiobiology of targeted radionuclide therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Front Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004403","article-title":"Immunostimulatory effects of radioimmunotherapy","volume":"10","author":"Constanzo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: Phase I trial of 177 Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0012","author":"Rohatgi"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0013","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet no. 21: A generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1109\/TNS.2006.869826","article-title":"Geant4 developments and applications","volume":"53","author":"Allison","year":"2006","journal-title":"IEEE Trans Nucl Sci"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0168-9002(03)01368-8","article-title":"Geant4\u2014a simulation toolkit","volume":"506","author":"Agostinelli","year":"2003","journal-title":"Nucl Instruments Methods Phys Res Sect A Accel Spectrometers, Detect Assoc Equip"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0016","article-title":"Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy","volume":"6","author":"Wen","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0017","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0018","first-page":"459","article-title":"A genomic profile of local immunity in the melanoma microenvironment following treatment with \u03b1 particle-emitting ultrasmall silica nanoparticles","volume":"35","author":"Urbanska","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0019","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2967\/jnumed.122.264752","article-title":"Targeted \u03b1-therapy using 225Ac radiolabeled single-domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment","volume":"64","author":"Ertveldt","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0020","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0021","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0022","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.7150\/thno.54881","article-title":"Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy","volume":"11","author":"Jagodinsky","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0023","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00259-022-05986-4","article-title":"Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant","volume":"50","author":"Jiang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0024","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3390\/cancers13153676","article-title":"Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of malignant melanoma","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0025","doi-asserted-by":"crossref","first-page":"86937","DOI":"10.18632\/oncotarget.13520","article-title":"Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas\u2019 sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation","volume":"7","author":"Malamas","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90 Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0027","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/acs.molpharmaceut.3c00427","article-title":"Effective treatment of SSTR2-positive small cell lung cancer using 211 at-containing targeted \u03b1-particle therapy agent which promotes endogenous antitumor immune response","volume":"20","author":"Qin","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0028","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7150\/thno.45540","article-title":"PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177 Lu-labeled \u03b1PD-L1 antibody","volume":"11","author":"Ren","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0029","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00262-020-02606-8","article-title":"Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy","volume":"69","author":"Rouanet","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0030","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1021\/acs.molpharmaceut.2c00361","article-title":"Evaluation of a radio-IMmunoStimulant (RIMS) in a syngeneic model of murine prostate cancer and immunoPET analysis of T-cell distribution","volume":"19","author":"\u015ami\u0142owicz","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0031","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.3390\/ijms22094843","article-title":"Combined radionuclide therapy and immunotherapy for treatment of triple negative breast cancer","volume":"22","author":"Vito","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0032","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0033","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2967\/jnumed.116.173559","article-title":"Remodeling the vascular microenvironment of glioblastoma with \u03b1-particles","volume":"57","author":"Behling","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1033303","article-title":"Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model","volume":"9","author":"Berg-Larsen","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0035","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1158\/1078-0432.CCR-08-0335","article-title":"The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell\u2013mediated killing","volume":"14","author":"Chakraborty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0036","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1 v \u03b2 3 -targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0037","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1667\/RADE-20-00237.1","article-title":"Low-dose radiation potentiates the propagation of anti-tumor immunity against melanoma tumor in the brain after in situ vaccination at a tumor outside the brain","volume":"195","author":"Clark","year":"2021","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2000699","article-title":"CS1-specific single-domain antibodies labeled with actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in multiple myeloma","volume":"10","author":"De Veirman","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0039","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-21-0791","article-title":"Targeted radionuclide therapy with low and high-dose lutetium-177\u2013labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model","volume":"21","author":"Ertveldt","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0040","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet no. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0041","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-07-4462","article-title":"T-cell responses to surviving in cancer patients undergoing radiation therapy","volume":"14","author":"Schaue","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0042","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","article-title":"Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response","volume":"101","author":"Zhang","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0044","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.molcel.2022.04.030","article-title":"DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production","volume":"82","author":"Uchihara","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0045","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0046","first-page":"110","article-title":"Immune defects in breast cancer patients after radiotherapy","volume":"6","author":"Standish","year":"2008","journal-title":"J Soc Integr Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0047","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cells10040930","article-title":"Biomarkers of radiotherapy-induced immunogenic cell death","volume":"10","author":"Vaes","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0048","doi-asserted-by":"crossref","first-page":"21588","DOI":"10.1074\/jbc.M110.193755","article-title":"Radiation-triggered tumor necrosis factor (TNF) \u03b1-NF\u03baB cross-signaling favors survival advantage in human neuroblastoma cells","volume":"286","author":"Veeraraghavan","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0049","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00262-023-03379-6","article-title":"Radiotherapy enhances CXCR3highCD8+ T cell activation through inducing IFN\u03b3-mediated CXCL10 and ICAM-1 expression in lung cancer cells","volume":"72","author":"Wang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0051","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0052","doi-asserted-by":"crossref","first-page":"542","DOI":"10.21037\/atm.2019.09.128","article-title":"Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines","volume":"7","author":"Huang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0053","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.21873\/anticanres.15821","article-title":"Comparative analysis of the antitumor immune profiles of paired radiotherapy-naive and radiotherapy-treated cervical cancer tissues","volume":"42","author":"Imamura","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0054","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s10495-014-1040-x","article-title":"Radiation-induced glioblastoma signaling cascade regulates viability, apoptosis and differentiation of neural stem cells (NSC)","volume":"19","author":"Ivanov","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1667\/RR14072.1","article-title":"Localized external beam radiation therapy (EBRT) to the pelvis induces systemic IL-1beta and TNF-alpha production: Role of the TNF-alpha signaling in EBRT-induced fatigue","volume":"185","author":"McDonald","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0056","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1667\/RR3189.1","article-title":"Crosstalk between Fas and JNK determines lymphocyte apoptosis after ionizing radiation","volume":"179","author":"Praveen","year":"2013","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.06.3855_bib0057","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jso.26261","article-title":"Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy","volume":"123","author":"Snow","year":"2021","journal-title":"J Surg Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:48:17Z","timestamp":1791654497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625044918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0360301625044918"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3855","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}